About US
Contact us
-
Genzyme obtains Mexican approval for multiple sclerosis drug LemtradaSanofi subsidiary Genzyme has received approval from Mexico's national regulatory authority COFEPRIS for its Lemtrada (alemtuzumab) to treat patients with relapsing remitting forms of multiple scleros2014/2/7
-
Teva secures FDA approval for new formulation of COPAXONEIsrael-based Teva Pharmaceuticals has received approval from the US Food and Drug Administration (FDA) for its supplemental new drug application (sNDA) for three-times-a-week COPAXONE 40mg/mL, a new d2014/1/30
-
Merck Statement on FDA Advisory Committee Meeting for RAGWITEK, an Investigational Sublingual Allergy Immunotherapy TabletMerck, known as MSD outside the US and Canada, is pleased with the positive discussion of RAGWITEK (Short Ragweed Pollen Allergen Extract) at the Allergenic Products Advisory Committee meeting of FDA.2014/1/30
-
EMA panel issues positive opinion for DSP and Takeda's schizophrenia drug lurasidoneJapanese firms Dainippon Sumitomo Pharma (DSP) and Takeda Pharmaceutical (Takeda) have received positive opinion from the European Medicines Agency's (EMA) Committee for Medicinal Products for Human U2014/1/29
-
Apricus gets national phase approval in Belgium for erectile dysfunction cream VitarosUS-based pharmaceutical firm Apricus Biosciences has received national phase approval from Belgium's Ministry of Social Affairs, Public Health and Environment for Vitaros, indicated for the treatment2014/1/29
-
FDA Prohibits Ranbaxy’s Toansa, India Facility from Producing and Distributing Drugs for the US MarketFDA hasnotified Ranbaxy Laboratories, Ltd, that it is prohibited from manufacturing and distributing APIs from its facility in Toansa, India, for FDA-regulated drug products. The Toansa facility is no2014/1/28
-
AstraZeneca and Bristol-Myers Squibb announce EU approval for diabetes drug XigduoThe European Commission has granted marketing authorisation to AstraZeneca and Bristol-Myers Squibb's (BMS's) Xigduo (dapagliflozin and metformin hydrochloride in 5mg/850mg and 5mg/1,000mg tablets) fo2014/1/28
-
FDA grants orphan drug status to BioLineRx's BL-8040 for stem cell mobilisation treatmentIsrael-based clinical-stage biopharmaceutical firm BioLineRx has received notice from the US Food & Drug Administration (FDA) confirming an Orphan Drug Designation for BL-8040 as a treatment for s2014/1/27
-
MIP Technologies AB Presents a New Range of Polymeric Separation Resins for Industrial UseMIP Technologies (a subsidiary of Biotage AB), a leading global supplier of solutions and technologies for specialty polymeric separation materials, is pleased to present a new range of RENSA industri2014/1/27
-
Bayer launches takeover offer for all shares of Algeta for €2.1bnBayer Nordic's subsidiary Aviator Acquisition has started the voluntary cash offer to acquire all the shares of Norwegian oncology firm Algeta for Nkr362 per share. The total value of the transaction2014/1/24